From WikiProjectMed
Jump to navigation Jump to search
Trade namesElucirem
  • 2-[3,9-bis[1-carboxylato-4-(2,3-dihydroxypropylamino)-4-oxobutyl]-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]-5-(2,3-dihydroxypropylamino)-5-oxopentanoate;gadolinium(3+)
Clinical data
Drug classGadolinium complex[1]
Main usesMRI contrast agent used to detect abnormal blood vessels[1]
Side effectsPain at the site of injection, headache, nausea, dizziness[1]
Routes of
Typical dose0.1 mL/kg[1]
License data
Legal status
Chemical and physical data
Molar mass970.10 g·mol−1
3D model (JSmol)
  • [Gd+3].OCC(O)CNC(=O)CCC(N1CCN(Cc2cccc(CN(CC1)C(CCC(=O)NCC(O)CO)C(=O)[O-])n2)C(CCC(=O)NCC(O)CO)C(=O)[O-])C(=O)[O-]
  • InChI=1S/C35H57N7O15.Gd/c43-19-24(46)14-36-30(49)7-4-27(33(52)53)40-10-12-41(28(34(54)55)5-8-31(50)37-15-25(47)20-44)17-22-2-1-3-23(39-22)18-42(13-11-40)29(35(56)57)6-9-32(51)38-16-26(48)21-45;/h1-3,24-29,43-48H,4-21H2,(H,36,49)(H,37,50)(H,38,51)(H,52,53)(H,54,55)(H,56,57);/q;+3/p-3

Gadopiclenol, sold under the brand name Elucirem, is a contrast agent used in magnetic resonance imaging (MRI) to detect lesions with abnormal blood vessels.[1] It may be used in those who are at least two years old.[1] It is given by injection into a vein.[1]

Common side effects include pain at the site of injection, headache, nausea, and dizziness.[1] Other side effects may include nephrogenic systemic fibrosis, allergic reactions, and retention of gadolinium.[1] Safety in pregnancy is unclear.[1] It is a paramagnetic macrocyclic non-ionic complex of gadolinium.[1]

Gadopiclenol was approved for medical use in the United States in 2022.[1] As of 2022 it is being looked at the approval agency in Europe.[3]

Medical use


It is generally given at a dose of 0.1 mL/kg.[1]


Gadopiclenol is the international nonproprietary name (INN).[4]


  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 "Elucirem- gadopiclenol injection". DailyMed. 12 October 2022. Archived from the original on 16 October 2022. Retrieved 16 October 2022.
  2. "Drug Approval Package: Elucirem". U.S. Food and Drug Administration (FDA). 20 October 2022. Archived from the original on 4 December 2022. Retrieved 4 December 2022.
  3. "FDA Approves Gadopiclenol for Contrast-Enhanced Magnetic Resonance Imaging". Pharmacy Times. Archived from the original on 27 September 2022. Retrieved 16 December 2022.
  4. World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80". WHO Drug Information. 32 (3). hdl:10665/330907.

External links

External sites:
  • Clinical trial number NCT03996447 for "Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) (PICTURE)" at
  • Clinical trial number NCT03986138 for "Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI) (PROMISE)" at